9,870 Shares in Bristol Myers Squibb Company $BMY Purchased by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 9,870 shares of the biopharmaceutical company’s stock, valued at approximately $532,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of BMY. Vanguard Group Inc. grew its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after acquiring an additional 2,743,759 shares during the period. State Street Corp raised its holdings in Bristol Myers Squibb by 2.0% during the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after purchasing an additional 1,855,238 shares during the last quarter. Geode Capital Management LLC raised its holdings in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Norges Bank purchased a new stake in Bristol Myers Squibb during the fourth quarter worth $1,947,272,000. Finally, Bank of New York Mellon Corp grew its holdings in Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The European Commission approved Opdivo plus AVD as the first immunotherapy-based frontline regimen for previously untreated stage III or IV classical Hodgkin lymphoma in the EU, which could expand Bristol Myers Squibb’s reach in a key oncology market. How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
• Positive Sentiment: At ASCO 2026, Bristol Myers Squibb highlighted promising late-stage cancer data, including Phase 3 results for mezigdomide in relapsed or refractory multiple myeloma and survival data for izalontamab brengitecan, reinforcing the company’s pipeline momentum. Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
• Positive Sentiment: Arcus Biosciences and Bristol Myers Squibb expanded their kidney cancer collaboration to advance casdatifan combinations in ccRCC, giving BMY another clinical-development opportunity in oncology. Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
• Neutral Sentiment: Several articles noted that Bristol Myers Squibb remains attractive to value and dividend-focused investors, with commentary pointing to its yield and dividend durability rather than a major near-term catalyst. Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
• Neutral Sentiment: Bristol Myers Squibb also drew attention from an options-volume report, suggesting heightened trading interest, though the item did not point to a specific fundamental driver. Bristol Myers Squibb Sees Unusually High Options Volume (NYSE:BMY)

Bristol Myers Squibb Stock Up 1.1%

Shares of NYSE:BMY opened at $57.24 on Friday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The company has a market capitalization of $116.88 billion, a P/E ratio of 16.08, a P/E/G ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock’s fifty day simple moving average is $58.10 and its 200-day simple moving average is $56.52.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. The firm had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BMY shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Cantor Fitzgerald boosted their price objective on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. Morgan Stanley restated an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Wall Street Zen downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Saturday. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.